Free Trial
NASDAQ:NKTX

Nkarta Q3 2023 Earnings Report

Nkarta logo
$1.81 +0.06 (+3.43%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$1.81 0.00 (0.00%)
As of 04/17/2025 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nkarta EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.67
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Nkarta Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nkarta Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 9, 2023
Conference Call Time
4:00PM ET

Upcoming Earnings

Nkarta's Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Nkarta Earnings Headlines

BMO Capital Markets Begins Coverage on Franco-Nevada (NYSE:FNV)
Franco-Nevada price target raised to $165 from $150 at Scotiabank
New “Trump” currency proposed in DC
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
See More Franco-Nevada Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nkarta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nkarta and other key companies, straight to your email.

About Nkarta

Nkarta (NASDAQ:NKTX), a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

View Nkarta Profile

More Earnings Resources from MarketBeat